uploads///Graph

Centene and Wellcare Health Plans: The Word on Wall Street

By

Oct. 11 2020, Updated 12:29 p.m. ET

Analysts’ recommendations and target price

Wall Street analysts expect an upside potential of 53.80% for Centene (CNC), based on the company’s trading price of $51.06. In 2019, analysts have revised the company’s target price upward from $78.10 in January to $78.53 in February and reiterated the target price of $78.53 in March.

Wall Street analysts expect an upside potential of 28.07% for WellCare Health Plans (WCG), based on the company’s trading price of $253.81. In 2019, analysts first raised the company’s target price from $308.00 in January to $326.38 in February before reducing it slightly to $325.06 in March.

The current consensus analyst recommendation for both Centene and WellCare Health Plans is “buy.”

Of the 19 analysts covering Centene, seven recommend a “strong buy,” nine recommend a “buy,” and three recommend a “hold.” The highest and lowest target price estimates for the company are $90 and $66, respectively.

Of the 15 analysts covering WellCare Health Plans, five recommend a “strong buy,” seven recommend a “buy,” and three recommend a “hold.” The highest and lowest target price estimates for the company are $360 and $298, respectively.

Article continues below advertisement

Deal synergies

According to a Centene–WellCare investor presentation, this deal is expected to become adjusted-EPS-accretive by a mid-single-digit percentage in the second full year after the transaction completes. Companies also expect to realize $500 million in cost synergies in the second full year after the deal’s completion.

According to the press release, the Centene–Wellcare Health Plans deal is expected to create managed care organization with pro forma fiscal 2019 revenues of $97 billion and proforma fiscal 2019 EBITDA of $5.0 billion. The combined company is expected to have 22 million members enrolled in government-sponsored programs across 50 US states. Plus, according to the press release, the combined company is also expected to have five million Medicare members, of which 1 million will be enrolled in Medicare plans while 4 million will be enrolled in Medicare PDP (Part D Program).

 

Advertisement

More From Market Realist

  • COVID-19 vaccine and Vaxart logo
    Healthcare
    Hate Injections? Vaxart Stock Might Be Attractive After the Crash
  • COVID-19 virus and Cocrystal Pharma logo
    Healthcare
    Cocrystal Pharma Stock Is a Speculative Play on COVID-19 Drug
  • Stethoscope and a smartphone
    Healthcare
    Why Bionovate Technologies (BIIO) Stock Is a Risky Bet in 2021
  • Precipio Biotech
    Healthcare
    Is Precipio (PRPO) a Good Stock to Buy? A Look at the Year Ahead
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.